my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
10-24-2011: Evotec AG and Apeiron Biologics AG announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.
Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation therefore can effectively enhance anti-tumor activities both for tumor antigen-specific cells and for those recognizing general features of tumor cells.
Evotec will apply their skills and proprietary technologies in cellular assay development and ultra-high throughput screening (uHTS) to identify biologically active molecules from its corporate library that interact with Cbl-b. The aim of the collaboration will be to take compounds identified by Evotec as being active against this target or other relevant targets and further jointly optimize them as basis for formal preclinical and clinical development.
No financial details are disclosed.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Apeiron Biologics AG announced that a clinical trial has started with the agent superoxide dismutase (project APN201) to investigate its potential for prevention of radiation dermatitis in breast cancer patients. Apeiron announced that a clinical trial has started with a liposomal topical ... more
Apeiron announced the initiation of a phase IIa clinical study of rhACE2, in patients with Acute Lung Injury (ALI). The study, of which Apeiron´s licensee GSK is sponsor, will include subjects with a positive diagnosis of ALI, and will be conducted in the intensive care units of multiple ho ... more
Evotec and APEIRON Biologics start next project on the Cbl-b target
Evotec AG and Apeiron Biologics AG announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation therefore can effectively enh ... more
Apeiron Biologics is engaged in the focused development of innovative therapeutics based on validated targets derived from biomedical break-through discoveries. The company, operational since 2005, was founded by Josef Penninger, a top level scientist with high international reputation and ... more
4-Antibody AG and Evotec AG Form Strategic Collaboration
4-Antibody AG and Evotec AG announced the signing of a strategic collaboration agreement under which Evotec will offer a fully integrated antibody discovery and development service. Evotec’s novel and unique high throughput and high content screening approach coupled with 4-Antibody’s high ... more
Evotec Achieves Two Milestones in Fragment-based Drug Discovery Alliance with Shionogi
Evotec AG announced the achievement of specific success criteria in a multiple target drug discovery collaboration with Shionogi & Co Ltd. and the receipt of two milestone payments. Evotec and Shionogi will continue to collaborate to progress the fragments through the drug discovery process ... more
Evotec and APEIRON Biologics start next project on the Cbl-b target
Evotec AG and Apeiron Biologics AG announced that they have entered into a further discovery project on the Cbl-b target, an excellent target for anti-tumor immune therapy.Cbl-b plays a role in both the adaptive and the innate immune system and its manipulation therefore can effectively enh ... more
Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more
Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
